Effects of statins on experimental colitis in normocholesterolemic rats

Scandinavian Journal of Gastroenterology

Volumn 41, Issue 8, 2006, Pages 954-962

  Jahovic, Nermina ^a   Gedik, Nursal ^b   Ercan, Feriha ^a   Şirvanci, Serap ^a   Yüksel, Meral ^c   Şener, Göksel ^c   Alican, Inci ^a  

^a MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b KASIMPASA MILITARY HOSPITAL   (Turkey)

^c MARMARA UNIVERSITY   (Turkey)

Author keywords

Colitis; Fluvastatin; Oxidant; Rat; Simvastatin

Indexed keywords

COLLAGEN; CYTOKINE; FLUINDOSTATIN; GLUTATHIONE; HYPOCHOLESTEROLEMIC AGENT; MALONALDEHYDE; MYELOPEROXIDASE; PEROXYNITRITE; REACTIVE OXYGEN METABOLITE; SIMVASTATIN; STATINE DERIVATIVE; SUPEROXIDE; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CHEMOLUMINESCENCE; COLITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVITY; LIPID PEROXIDATION; MONITORING; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME;

ANIMALS; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; COLITIS; COLLAGEN; COLON; FATTY ACIDS, MONOUNSATURATED; GLUTATHIONE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; LUMINESCENCE; MALONDIALDEHYDE; PEROXIDASE; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; SIMVASTATIN; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33745684509     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520600554444     Document Type: Article

References (48)

1. Corsini A, Maggi FM, Catapano AL. Pharmacology of competitive inhibitors of HMG-CoA reductase. Pharmacol Res 1995;31:9-27.
2. Simes J, Furberg CD, Braunwald E, Davis BR, Ford I, Tonkin A, et al. Effects of pravastatin on mortality of patients with and without coronary heart disease across a broad range of cholesterol levels. Eur Heart 2002;23:207-15.
3. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
4. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. J Am. Med Assoc 1998;279:1615-22.
5. Plutzky J, Ridker PM. Statins for stroke. Circulation 2001;103:348-50.
6. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, et al. Effect on pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995;333:621-7.
7. Wenke K, Meiser B, Thiery J, Nagel D, von Scheidt W, Steinbeck G, et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation. Circulation 1997;96:1398-402.
8. Diomede L, Albani D, Sottocorno M, Donati MB, Bianchi M, Fruscella P, et al. In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products. Arterioscler Thromb Vasc Biol 2001;21:1327-32.
9. Kimura M, Kurose I, Russell J, Granger DN. Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats. Arterioscler Thromb Vasc Biol 1997;17:1521-226.
10. Stalker TJ, Lefer AM, Scalia R. A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid. Br J Pharmacol 2001;133:406-12.
11. Stanislaus R, Singh AK, Singh I. Lovastatin treatment decreases mononuclear cell infiltration into the CNS of Lewis rats with experimental allergic encephalomyelitis. J. Neurosci Res 2001;66:155-62.
12. Rea WE, Durrant DCS, Boldy DAR. Ulcerative colitis after statin treatment. Postgrad Med J 2002;78:286-7.
13. Kiener PA, Davis PM, Murat JL, Youssef S, Rankin BM, Kowala M. Stimulation of inflammatory responses in vitro and in vivo by lipophilic HMG-CoA reductase inhibitors. Int. Immunopharmacol 2001;1:105-18.
14. Morris GP, Beck PL, Herridge MS, Depw WT, Szewczuk MR, Wallace JL. A hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 1989;96:795-803.
15. Wallace JL, Braquet P, Ibbotson GC, MacNaugton WK, Cirino G. Assessment of the role of platelet activating factor in an animal model of inflammatory bowel disease. J Lipid Mediat 1989;1:13-23.
16. Gue M, Bonbonne C, Fioramonti J, More J, Del RioLacheze C, Comera C, et al. Stress-induced enhancement of colitis in rats: CRF and arginine vasopressin are not involved. Am J Physiol 1987;272:84-91.
17. Aykaç G, Uysal M, Yalçin AS, Koçak-Toker N, Sivas A, Öz H. The effect of chronic ethanol ingestion on hepatic lipid peroxide, glutathione peroxidase and glutathione transferase in rats. Toxicology 1985;36:71-6.
18. Casini A, Ferrali M, Pompella AS, Maellaro E, Comporti M. Lipid peroxidation and cellular damage in extrahepatic tissues of bromobenzene toxicated mice. Am J Pathol 1986;123:520-31.
19. Bradley PP, Priebat DA, Christensen RD, Rothstein G. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol 1982;78:206-9.
20. Haklar G, Ulukaya-Durakbaşa C, Yüksel M, Daǧli T, Yalçin AS. Oxygen radicals and nitric oxide in rat mesenteric ischemia-reperfusion: modulation by L-arginine and N-nitro-L-arginine methyl ester. Clin Exp Pharmacol Physiol 1998;25:908-12.
21. Lopez De Leon A, Rojkind M. A simple micromethod for collagen and total protein determination in formalin-fixed paraffin-embedded sections. J Histochem Cytochem 1985;33:737-43.
22. Elson CO, Sartor RB, Tennyson GS, Riddell RH. Experimental models of inflammatory bowel disease. Gastroenterology 1995;109:1344-67.
23. Grisham MB, Volkmer C, Tso P, Yamada T. Metabolism of trinitrobenzene sulfonic acid by the rat colon produces reactive oxygen species. Gastroenterology 1991;101:540-7.
24. Siems WG, Grune T, Werner A, Gerber G, Buntrock P, Scheider W. Protective influence of oxypurinol on the trinitrobenzene sulfonic acid (TNBS) model of inflammatory bowel disease in rats. Cell Mol Biol 1992;38:189-99.
25. Haklar G, Özveri ES, Yüksel M, Aktan AÖ, Yalçin AS. Different kinds of reactive oxygen and nitrogen species were detected in colon and breast tumors. Cancer Lett 2001;165:219-24.
26. Davies GR, Simmonds NJ, Stevens TR, Sheaff MT, Banatvala N, Laurenson IF, et al. Helicobacter pylori stimulates antral mucosal reactive oxygen metabolite production in vivo. Gut 1994;35:179-85.
27. O'Hara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 1993;92:2546-51.
28. Grisham M, Granger DN. Neutrophil-mediated mucosal injury, role of reactive oxygen metabolites. Dig Dis Sci 1988;33:6-15.
29. Kitahora T, Suzuki K, Asakura H, Yoshida T, Suematsu M, Watanabe M, et al. Active oxygen species generated by monocytes and polymorphonuclear cells in Crohn's disease. Dig Dis Sci 1988;33:951-5.
30. Williams JG, Hughes LE, Hallett MB. Toxic oxygen metabolite production by circulating phagocyting cells in inflammatory bowel disease. Gut 1990;31:187-93.
31. Hermaowicz A, Gibson PR, Jewell DP. The role of phagocytes in inflammatory bowel disease. Clin Sci 1985;69:241-59.
32. Wallace JL, McKnight W, Asfaha S, Lio DY. Reduction of acute and reactivated colitis in rats by an inhibitor of neutrophil activation. Am J Physiol 1998;274:G802-8.
33. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlan P W, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
34. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332:481-7.
35. Delanty N, Vaughan CJ. Vascular effects of statins in stroke. Stroke 1997;28:2315-20.
36. Lefer A M, Campbell B, Shin YK, Scalia R, Hayward R, Lefer DJ. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation 1999;100:178-84.
37. Osborn JA, Lento PH, Siegfried MR, Stahl GL, Fusman B, Lefer AM. Cardiovascular effects of acute hypercholesterolemia in rabbits. Reversal with lovastatin treatment. J Clin Invest 1989;83:465-73.
38. Kinlay S, Selwyn AP, Delagrange D, Creager MA, Libby P, Gantz P. Biological mechanisms for the clinical success of lipid-lowering in coronary artery disease and use of surrogate end-points. Curr Opin Lipid 1996;7:389-97.
39. Mital S, Zhang X, Zhao G, Bernstein RD, Smith CJ, Fulton D, et al. Simvastatin up-regulates coronary vascular endothelial nitric oxide production in conscious dogs. Am J Physiol 2000;279:H2649-57.
40. Dunzendorfer S, Rothbucher D, Schratzberger P, Reinisch N, Kanler CM, Wiedermann CJ. Mevalonate-dependent inhibition of transendothelial migration and chemotaxis of human peripheral blood neutrophils by provastatin. Circ Res 1997;81:963-9.
41. Weber C, Erl W, Weber KS, Weber PC. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol 1997;30:1212-7.
42. Bustos C, Hernandex-Presa MA, Ortego M, Tunon J, Ortega L, Perez F, et al. HMG-CoA-reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol 1998;32:2057-64.
43. Ferro D, Parrotto S, Basili S, Alessandri C, Violi F. Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. J Am Coll Cardiol 2000;36:427-31.
44. Grip O, Janciauskiene S, Lindgren S. Pravastatin down-regulates inflammatory mediators in human monocytes in vitro. Eur J Pharmacol 2000;410:83-92.
45. Sparrow CP, Burton CA, Hernandez M, Mundt S, Hassing H, Patel S, et al. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol 2001;21:115-21.
46. Pruefer D, Makowski J, Schnell M, Buerke U, Dahm M, Oelert H, et al. Simvastatin inhibits inflammatory properties of Staphylococcus aureus α-toxin. Circulation 2002;106:2104-10.
47. Suzumura K, Yasuhara M, Tanaka K, Odawara A, Narita H, Suzuki T. An in vitro study of the hydroxyl radical scavenging property of fluvastatin, and HMG-CoA reductase inhibitor. Chem Pharm Bul 1999;47:1010-2.
48. Franzoni F, Quinones-Galvan A, Regoli F, Ferrannini E, Galetta F. A comparative study of the in vitro antioxidant activity of statins. Int J Cardiol 2003;90:317-21.